BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 15528270)

  • 1. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
    Dutertre M; Smith CL
    Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
    Al-Dhaheri MH; Rowan BG
    Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
    Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
    J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.
    Feng W; Webb P; Nguyen P; Liu X; Li J; Karin M; Kushner PJ
    Mol Endocrinol; 2001 Jan; 15(1):32-45. PubMed ID: 11145737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.
    Bai Y; Giguére V
    Mol Endocrinol; 2003 Apr; 17(4):589-99. PubMed ID: 12554772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells.
    Klinge CM; Jernigan SC; Risinger KE
    Endocrinology; 2002 Mar; 143(3):853-67. PubMed ID: 11861507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity.
    Likhite VS; Stossi F; Kim K; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 2006 Dec; 20(12):3120-32. PubMed ID: 16945990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERalpha transcriptional activity and MCF-7 proliferation.
    Cavarretta IT; Mukopadhyay R; Lonard DM; Cowsert LM; Bennett CF; O'Malley BW; Smith CL
    Mol Endocrinol; 2002 Feb; 16(2):253-70. PubMed ID: 11818499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.
    Weis KE; Ekena K; Thomas JA; Lazennec G; Katzenellenbogen BS
    Mol Endocrinol; 1996 Nov; 10(11):1388-98. PubMed ID: 8923465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene.
    Levy N; Zhao X; Tang H; Jaffe RB; Speed TP; Leitman DC
    Endocrinology; 2007 Jul; 148(7):3449-58. PubMed ID: 17395694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.
    Métivier R; Penot G; Flouriot G; Pakdel F
    Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator.
    Narayanan R; Adigun AA; Edwards DP; Weigel NL
    Mol Cell Biol; 2005 Jan; 25(1):264-77. PubMed ID: 15601848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells.
    Lee TH; Chuang LY; Hung WC
    Oncogene; 2000 Aug; 19(33):3766-73. PubMed ID: 10949931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
    Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS
    Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
    Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRA coactivation of estrogen receptor-alpha is phosphorylation-independent, and enhances 4-hydroxytamoxifen agonist activity.
    Coleman KM; Lam V; Jaber BM; Lanz RB; Smith CL
    Biochem Biophys Res Commun; 2004 Oct; 323(1):332-8. PubMed ID: 15351741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.